The global market for therapeutics targeting IgG4-related disease is observing substantial expansion. Driven by an rising prevalence of these inflammatory conditions and the introduction of novel treatment solutions, the market is poised for remarkable opportunities in the near future. Key contributors propelling this expansion include a rising und